Current stock page

Catalysts

RVMD Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

RVMDRevolution Medicines, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$172.29−$4.06 (−2.30%)

Latest quote

  • Momentum
    73
  • Value
    39
  • Quality
    43
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 24, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 55/100

Momentum 73/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 28.20%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 73/100AIQ Edge 5/10 In Line With Peers
Beat rate
13%
1 of 8 reported periods
Average surprise
-14.2%
Across covered historical reports
Latest result
+19.1%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—-$2.35-$1.90+19.1%$25.58M$197.6M
Aug 5, 2026—-$2.04-$3.06-50.0%$1.77M—
May 6, 2026—-$1.84-$2.29-24.5%$2.43M—
Feb 25, 2026—-$1.58-$1.86-17.7%$3.68M—
Nov 5, 2025—-$1.42-$1.61-13.4%$1.69M—
Aug 6, 2025—-$1.14-$1.31-15.1%$27.53M—
May 7, 2025—-$1.12-$1.13-0.9%$1.2M—
Feb 26, 2025—-$1.01-$1.12-10.9%$375K—

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
24
Buy
1
Hold
12-month analyst target
$262.36
+52.28% versus current price
Based on 25 analyst observations. Targets are estimates, not predictions.
Low target
$179.00
+3.89% vs latest price
Average target
$262.36
+52.28% vs latest price
High target
$320.00
+85.73% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 24, 2027

Next known earnings or reporting date.

EPS estimate-$1.22

Current analyst expectation for the upcoming report.

Revenue estimate$388.66M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score73

Where event reaction would show up first.

AIQ score55/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
25
Average target
$262.36
Target upside
52.28%
Target range
$179.00 - $320.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
0
Negative
1
seekingalpha.com · Nov 12, 2026

Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High

Revolution Medicines has transitioned to commercial operations with a strong initial RASONQUE launch. See why I rate RVMD stock as Buy. Read my analysis.

zacks.com · Nov 4, 2026

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates

Revolution Medicines (RVMD) delivered earnings and revenue surprises of +18.80% and +596.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

insidermonkey.com · Oct 20, 2026

Revolution Medicines (RVMD) Has an Approved Cancer Drug. Can Its $38 Billion Valuation Deliver?

Approval Was the First Hurdle, Not the Last Revolution Medicines, Inc. (NASDAQ:RVMD) is no longer valuing a theoretical pancreatic cancer drug.

gurufocus.com · Oct 19, 2026

RVMD Maintained by Truist Securities -- Price Target Raised to $241

On October 16, 2026, Truist Securities maintained a "Buy" rating on Revolution Medicines (RVMD). The price target has been adjusted from $240.00 to $241.00, ref

Open full news and sentiment

RVMD Catalysts FAQ

What are the next catalysts for RVMD stock?

RVMD's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move RVMD stock?

Upcoming events that could move RVMD include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could RVMD's next earnings report affect the stock?

RVMD's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive RVMD stock higher?

RVMD could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt RVMD stock?

RVMD could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.